ALUR (Allurion Technologies) EBITDA Margin % : -162.49% (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Allurion Technologies EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Allurion Technologies's EBITDA for the three months ended in Sep. 2024 was $-8.72 Mil. Allurion Technologies's Revenue for the three months ended in Sep. 2024 was $5.37 Mil. Therefore, Allurion Technologies's EBITDA margin for the quarter that ended in Sep. 2024 was -162.49%.

Allurion Technologies EBITDA Margin % Historical Data

The historical data trend for Allurion Technologies's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allurion Technologies EBITDA Margin % Chart

Allurion Technologies Annual Data

Trend

Dec21

Dec22

Dec23

EBITDA Margin %

-20.95

-50.27

-129.11

Allurion Technologies Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBITDA Margin %	Get a 7-Day Free Trial							-103.58	-189.23	84.81	-13.27	-162.49

Competitive Comparison of Allurion Technologies's EBITDA Margin %

For the Medical Devices subindustry, Allurion Technologies's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allurion Technologies's EBITDA Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Allurion Technologies's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Allurion Technologies's EBITDA Margin % falls into.

Allurion Technologies EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Allurion Technologies's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-69.031	/	53.467
	=	-129.11 %

Allurion Technologies's EBITDA Margin % for the quarter that ended in Sep. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-8.721	/	5.367
	=	-162.49 %

Allurion Technologies (NYSE:ALUR) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Allurion Technologies EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Allurion Technologies's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Allurion Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Allurion Technologies Inc (NYSE:ALUR) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

11 Huron Drive, Natick, MA, USA, 01760

Website

https://www.allurion.com

Allurion Technologies Inc is a medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.

Executives

Omar Ishrak	director	710 MEDTRONIC PKWY, MS LC300, MINNEAPOLIS MN 55432
Nicholas Sheridan Lewin	director	3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Krishna K. Gupta	director, 10 percent owner	307 HARVARD ST, CAMBRIDGE MA 02139
Christopher J Geberth	officer: Chief Financial Officer	11 HURON DRIVE, SUITE 200, NATICK MA 01760
Michael R Davin	director	C/O CYNOSURE, INC., 5 CARLISLE ROAD, WESTFORD MA 01886
Larson Douglas Hudson	director	11 HURON DRIVE, SUITE 200, NATICK MA 01760
Benoit Chardon	officer: Chief Commercial Officer	11 HURON DRIVE, SUITE 200, NATICK MA 01760
Shantanu Gaur	director, officer: Chief Executive Officer	11 HURON DRIVE, SUITE 200, NATICK MA 01760
Ram Chuttani	officer: Chief Medical Officer	11 HURON DRIVE, SUITE 200, NATICK MA 01760